Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
August 07 2020 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT
Blood Systems disposable kit shipments have surpassed 7.5 million
treatable platelet and plasma doses globally since commercial
launch.
“This is a significant milestone for Cerus and highlights the
scope our technology has had within the transfusion industry and on
the millions of patients worldwide transfused with INTERCEPT
treated platelet and plasma components,” said William ‘Obi’
Greenman, Cerus’ president and chief executive officer. “We have a
solid track record with the safety and efficacy of our INTERCEPT
products, which now surpasses more than 7.5 million treatable
doses.”
The INTERCEPT Blood System for platelets and plasma provides a
proactive approach to reduce the risk of transfusion-transmitted
infectious disease (TTID). Cerus’ proprietary pathogen-reduction
technology provides a foundational strategy for safeguarding the
blood supply against a broad spectrum of known and emerging
pathogens. Annually, over 115 million units of blood are donated
worldwide and there is no therapeutic alternative for patients who
need blood1.
About the Cerus INTERCEPT Blood System:
- Provides robust, broad-spectrum reduction of the risks of TTID,
including sepsis, and can be used to replace bacterial detection,
cytomegalovirus (CMV) and Babesia testing and gamma irradiation for
prevention of transfusion-associated graft-versus-host disease
(TA-GVHD).
- INTERCEPT Blood System for platelets and plasma utilizes
amotosalen, a photoactive compound activated with ultra-violet
light that specifically targets DNA and RNA, irreversibly
cross-linking nucleic acids, which blocks the replication of
viruses, bacteria, and parasites.
- Over a decade of national hemovigilance data on INTERCEPT
treated platelets establishing a proven track record of safety and
clinical utility . The INTERCEPT Blood System for platelets is now
the standard of care in nine countries including France,
Switzerland, Belgium, and Austria.‡
- INTERCEPT complies with the FDA guidance on bacterial safety in
platelets and also provides a proactive solution to address
pandemic preparedness.
- A recent study conducted at the King Abdulaziz University in
Jeddah Saudi Arabia demonstrated that INTERCEPT Blood System
inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma
components.
- The use of INTERCEPT provides an alternative to the three-month
donor deferral period for residents of non-malaria endemic
countries after traveling to malaria-endemic regions, thereby
potentially improving blood component availability for hospitals,
blood banks, and ultimately, patients in need.
‡ Standard of care defined as treating greater than 50% of
platelets
- World Health Organization,
https://www.who.int/news-room/facts-in-pictures/detail/blood-transfusion
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200807005112/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024